Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0WYNIR
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Enoblituzumab-ADC-24-10
|
|||||
| Synonyms |
Enoblituzumab ADC 24 10
Click to Show/Hide
|
|||||
| Organization |
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 2 Indication(s)
Glioblastoma [ICD11:2A00]
Investigative
Oropharynx squamous cell carcinoma [ICD11:2B6A]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4-8
|
|||||
| Structure |
|
|||||
| Antibody Name |
Enoblituzumab
|
Antibody Info | ||||
| Antigen Name |
CD276 antigen (CD276)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
Enoblituzumab-ADC-24-10 linker
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.